



Miltenyi Biotec

# Engineered T cell manufacturing

Endless possibilities for innovations in cell therapy



# Flexible and customizable options for T cell therapy

## Experience and success in cell manufacturing

For decades, Miltenyi Biotec has been a driving force in the development of cell manufacturing processes. In a series of instrument, reagent, and software innovations, our products and services have sparked a transition in cell processing. Time-consuming and variable manual handling is now highly standardized state-of-the-art automation.

The CliniMACS Prodigy® Platform catalyzes progress especially in T cell engineering. The instrument fosters the seamless transition of novel therapeutic strategies to clinical deployment. At the same time, it maintains a focus on consistently generating high-quality cell products.

## A spectrum of options in T cell engineering

The CliniMACS Prodigy is the manufacturing platform of choice for numerous next-generation T cell therapies, including bispecific<sup>1</sup>, switchable<sup>2</sup>, and armored<sup>3</sup> CAR constructs, plus non-viral<sup>4</sup> and TCR engineering<sup>5</sup>.

Three production processes underlie that diversity. The CliniMACS Prodigy T Cell Transduction (TCT) process automates efficient T cell isolation and viral transduction from a range of starting materials (Table 1). Larger volumes are managed with its large-scale counterpart, TCT-LS. Interested in electroporation for your workflow? The CliniMACS Prodigy T Cell Engineering (TCTe) process offers that option. Finally, our Customized Application Services can develop a tailored formulation and filling with the CliniMACS® Formulation Unit.

	CliniMACS Prodigy T Cell Transduction (TCT)	CliniMACS Prodigy T Cell Transduction Large Scale (TCT-LS)	CliniMACS Prodigy T Cell Engineering (TCTe)
Main manufacturing application	CAR T cells	TCR T cells and CAR T cells for solid tumors	Complex engineered T cells
<b>Starting material</b>			
Whole blood <sup>6</sup>	●		●
Buffy coat	●		●
Fresh leukapheresis	●	●	●
Frozen leukapheresis		●	
<b>Gene engineering method</b>			
Lentivirus/retrovirus transduction	●	●	●
Electroporation			●
Culture capacity	250 mL	600 mL	250 mL
<b>Number of harvested cells</b>			
Without electroporation	5×10 <sup>9</sup>	2×10 <sup>10</sup>	5×10 <sup>9</sup>
With electroporation			2×10 <sup>9</sup>


**Table 1:** Overview of the three flexible and customizable processes for T cell therapy manufacturing available on the CliniMACS Prodigy Platform.

LEARN MORE




**One platform. Endless possibilities.**  
Get an overview of our manufacturing options for gene-engineered T cells.  
► [miltenyibiotec.com/engineeredTcells](https://miltenyibiotec.com/engineeredTcells)


## T Cell Transduction (TCT)



## T Cell Transduction – Large Scale (TCT-LS)



## T Cell Engineering (TCTe)




# No hurdles or limits. Just answers and options.

## Integrated cell processing from collection to harvest


The CliniMACS Prodigy TCT, TCT-LS, and TCTe processes integrate optimized cell processing conditions within the protective, sterile environment of the closed CliniMACS Prodigy Platform. Each step overcomes known hurdles in T cell engineering to generate reproducible end products. Plus, automation eliminates variable material handling for standardized outcomes.

## High-purity start. Reproducible results.

Effective cell manufacturing starts with a well-defined, enriched T cell population. Our three processes use clinical-scale magnetic separation to yield highly pure and viable T cells, even from patient material (internal data; fig. 1). The low monocyte content of the enriched T cells enhances transduction efficiency (fig. 2), cutting the amount and cost of vector input.



**Figure 1:** Automated enrichment with the CliniMACS Prodigy TCT, TCT-LS, or TCTe processes generates highly reproducible and pure T cell populations. The composition of enriched material from fresh (green) and frozen (blue) samples of healthy donors (top) and patients (bottom) is optimal for downstream steps.



**Figure 2:** Unwanted cells reduce transduction efficiency significantly. A doubling in the relative proportion of monocytes in a sample lowers transduction efficiency from 50 to under 20%.

## Robust and straightforward stimulation

The ready-to-use reagent MACS® GMP T Cell TransAct™ and its large-scale counterpart achieve potent polyclonal activation of cells in preparation for gene modification. Designed for use in a closed manufacturing system, MACS GMP T Cell TransAct is easy to use. Excess of the unique colloidal polymeric nanomatrix is simply washed away after stimulation.

## Transduction or transfection? Your choice.

Our three T cell manufacturing processes cover lentivirus, retrovirus, and transfection-based gene modification (figs. 3 and 4). The process occurs in the closed CliniMACS Prodigy Tubing Set, ensuring safety when using viral vectors. Choose one or combine methods to efficiently perform even complex editing. The engineering step is customizable, granting full control to adapt timing, volumes, multiplicity of infection (MOI), electroporation settings, and more. Whether gene transduction, knockout, augmentation, silencing, or editing, the possibilities are endless.

## Simple and convenient T cell activation



### Practical application

- Volumetric dosage
- Ready-to-use
- Removal by simple washing




### Robust stimulation

- Highest cell viability
- Physiological and stable stimulation




### Convenient compatibility

- Available for research and GMP T cell workflows
- Optimized for CAR T cell production on the CliniMACS Prodigy
- Can be sterile filtered



**Figure 3:** Enriched CD4<sup>+</sup> and CD8<sup>+</sup> T cells were stimulated for 24 hours before transduction using lentiviral vectors encoding CAR or TCR. The CliniMACS Prodigy TCT-LS achieved adequate and stable transduction rates.



**Figure 4:** The gene for CCR5 was edited using transcription activator-like effector nucleases (TALENs) combined with the CliniMACS Electroperator. Editing rates at two and nine days after electroporation were comparable. Rates were calculated from gene-editing frequency digital PCR (GEF-dPCR) data (n=4).

LEARN MORE



### Simplified T cell activation


Discover the unique features of MACS GMP T Cell TransAct.

► [miltenybiotec.com/GMP-TransAct](https://miltenybiotec.com/GMP-TransAct)


# No slowdowns or complications. Just seamless progress.

## Optimal expansion to meet dosing goals


Two in-line cultivation chamber sizes house the fitting conditions to achieve standard and large-scale cell expansion (fig. 5). Each process features a ready-to-use default protocol that quickly and robustly grows the preferable T cell phenotype (fig. 6) from fresh or frozen material (fig. 7). However, cultivation parameters are programmable. Customize the culture duration, medium supply, and supernatant exchange to optimize growth or shorten manufacturing.



**Figure 5:** The CliniMACS Prodigy TCT-LS process features an expanded culture chamber (right) for large-scale production compared to the CliniMACS Prodigy TCT and TCTe (left).




**Figure 6:** Frequencies of T cell phenotypes among viable CD45<sup>+</sup> cells were determined for the final cell product from enriched CD4<sup>+</sup>/CD8<sup>+</sup> T cells that were expanded in the standard and large-scale chamber of the CliniMACS Prodigy after polyclonal stimulation with MACS GMP T Cell Transact. After 12 days of culture, phenotype frequencies were comparable between the two culture conditions.



**Figure 7:** After polyclonal stimulation, enriched CD4<sup>+</sup>/CD8<sup>+</sup> T cells from frozen and fresh samples were expanded in the presence of different cytokines using the standard chamber of the CliniMACS Prodigy TCT process (dotted lines) and the large-scale chamber of the CliniMACS Prodigy TCT-LS process (solid lines). Cell expansion was comparable between fresh material, frozen material, and different cytokine combinations. That consistency underscores the robustness of the process.

## Aligned and reliable end-to-end IPC/RT

From in-process control (IPC) to release testing (RT), flow cytometric analysis of cell phenotype, count, function, and quality goes hand in hand with manufacturing processes on the CliniMACS Prodigy Platform. The MACSQuant® Analyzer 16, StainExpress™ dry antibody cocktails, and Express Mode software tools seamlessly interface with your production workflow and provide automated data flows for precise and consistent analyses.



## The right tools at every step

IPC/RT		TCT-LS (CliniMACS Prodigy Tubing Set 620)	TCT (CliniMACS Prodigy Tubing Set 520)	TCTe (CliniMACS Prodigy Tubing Set 520)
	Magnetic enrichment	TexMACS™ GMP Medium CliniMACS PBS/EDTA Buffer CliniMACS CD4 Product Line and CliniMACS CD8 Product Line or CliniMACS CD62L Reagent CR/GMP		
	Activation	MACS GMP TransAct – Large Scale	MACS GMP TransAct	
	Transduction/electroporation	Lentiviral vector or gamma retroviral vector		Gene editing tools
	Cultivation	TexMACS GMP Medium MACS GMP Cytokines		
	Formulation	CliniMACS Formulation Solution		

**LEARN MORE**

**The perfect match**  
Learn how the MACSQuant Analyzers and CliniMACS Prodigy were made for one another.  
▶ [miltenyibiotec.com/perfect-match](https://miltenyibiotec.com/perfect-match)

**VISIT**

**Discover more**  
Read other clinical research papers that reference the CliniMACS Prodigy.  
▶ [miltenyibiotec.com/Tcell-engineering-refs](https://miltenyibiotec.com/Tcell-engineering-refs)

## References

1. Shah, N. N. *et al.* (2020) *Nat. Med.* 26: 1569–1575.
2. Loff, S. *et al.* (2020) *Mol. Ther. Oncolytics* 17: 408–420.
3. Glienke, W. *et al.* (2022) *Front. Immunol.* 13: 839783.
4. Lock, D. *et al.* (2022) *J. Immunother. Cancer* 10: e005189.
5. Foy, S. *et al.* (2023) *Nature* 615: 687–696.
6. Lock, D. *et al.* (2017) *Hum. Gene Ther.* 28: 914–925.

# ► [miltenyibiotec.com/engineeredTcells](http://miltenyibiotec.com/engineeredTcells)



**Miltenyi Biotec**

## **Germany/Austria**

Miltenyi Biotec B.V. & Co. KG  
Friedrich-Ebert-Straße 68  
51429 Bergisch Gladbach  
Germany  
Phone +49 2204 8306-0  
Fax +49 2204 85197  
macsde@miltenyi.com

## **USA/Canada**

Miltenyi Biotec, Inc.  
2303 Lindbergh Street  
Auburn, CA 95602, USA  
Phone 800 FOR MACS  
Phone +1 866 811 4466  
Fax +1 877 591 1060  
macsus@miltenyi.com

## **Australia**

Miltenyi Biotec  
Australia Pty. Ltd.  
Unit 11, 2 Eden Park Drive  
Macquarie Park, NSW 2113  
Australia  
Phone +61 2 8877 7400  
Fax +61 2 9889 5044  
macsau@miltenyi.com

## **France**

Miltenyi Biotec SAS  
10 rue Mercœur  
75011 Paris, France  
Phone +33 1 56 98 16 16  
macsfr@miltenyi.com

## **Benelux**

Miltenyi Biotec B.V.  
Dellaertweg 9C  
2316 WZ Leiden  
The Netherlands  
macsnl@miltenyi.com  
**Customer service for:  
The Netherlands**  
Phone 0800 4020120  
Fax 0800 4020100

## **Belgium**

Phone 0800 94016  
Fax 0800 99626

## **Luxembourg**

Phone 800 24971  
Fax 800 24984

## **China**

Miltenyi Biotec Technology &  
Trading (Shanghai) Co., Ltd.  
Room A401, 4/F  
No. 1077, Zhangheng Road  
Pudong New Area  
201203 Shanghai, P.R. China  
Phone +86 21 6235 1005-0  
Fax +86 21 6235 0953  
macscn@miltenyi.com.cn

## **France**

Miltenyi Biotec SAS  
10 rue Mercœur  
75011 Paris, France  
Phone +33 1 56 98 16 16  
macsfr@miltenyi.com

## **Hong Kong**

Miltenyi Biotec Hong Kong Ltd.  
Unit 301, Lakeside 1  
No. 8 Science Park West Avenue  
Hong Kong Science Park  
Pak Shek Kok, New Territories  
Hong Kong  
Phone +852 3751 6698  
Fax +852 3619 5772  
macshk@miltenyi.com.hk

## **India**

Miltenyi Biotec India Pvt. Ltd.  
Vatika Business Centre,  
Floor No. 6  
Divya Sree Omega  
Kondapur, Serilingampally  
K.V. Rangareddy  
Telangana 500084, India  
Phone +91 040 45175910  
macsin@miltenyi.com

## **Italy**

Miltenyi Biotec S.r.l.  
Via Paolo Nanni Costa, 30  
40133 Bologna, Italy  
Phone +39 051 6 460 411  
Fax +39 051 6 460 499  
macsit@miltenyi.com

## **Japan**

Miltenyi Biotec K.K.  
NEX-Eitai Building 5F  
16-10 Fuyuki, Koto-ku  
Tokyo 135-0041, Japan  
Phone +81 3 5646 8910  
Fax +81 3 5646 8911  
macsjp@miltenyi.com

## **Nordics and Baltics**

Miltenyi Biotec Norden AB  
Medicon Village  
Scheeleorget 1  
223 81 Lund, Sweden  
macsse@miltenyi.com  
**Customer service for:  
Sweden**  
Phone 0200 111 800  
Fax +46 280 72 99

## **Denmark**

Phone 80 20 30 10  
Fax +46 46 280 72 99

## **Norway, Finland, Iceland, and Baltic countries**

Phone +46 46 280 72 80  
Fax +46 46 280 72 99

## **Singapore**

Miltenyi Biotec Asia Pacific Pte Ltd.  
438B Alexandra Road, Block B  
Alexandra Technopark  
#06-01  
Singapore 119968  
Phone +65 6238 8183  
Fax +65 6238 0302  
macssg@miltenyi.com

## **South Korea**

Miltenyi Biotec Korea Co., Ltd.  
Donggeuk 7F,  
562 Nonhyeon-ro  
Gangnam-gu  
Seoul 06136, South Korea  
Phone +82 2 555 1988  
Fax +82 2 555 8890  
macskr@miltenyi.com

## **Spain**

Miltenyi Biotec S.L.  
C/Virgilio 2, Edificio II, Planta -1  
28223 Pozuelo de Alarcón  
Madrid, Spain  
Phone +34 91 512 12 90  
Fax +34 91 512 12 91  
macses@miltenyi.com

## **Switzerland**

Miltenyi Biotec Swiss AG  
Soodstrasse 52  
8134 Adliswil  
Switzerland  
Phone +41 32 623 08 47  
Fax +49 2204 85197  
macsch@miltenyi.com

## **United Kingdom**

Miltenyi Biotec Ltd.  
Almac House, Church Lane  
Bisley, Surrey GU24 9DR, UK  
Phone +44 1483 799 800  
Fax +44 1483 799 811  
macsuk@miltenyi.com

[www.miltenyibiotec.com](http://www.miltenyibiotec.com)

Miltenyi Biotec provides products and services worldwide. Visit [www.miltenyibiotec.com/local](http://www.miltenyibiotec.com/local) to find your nearest Miltenyi Biotec contact.

Unless otherwise specifically indicated, Miltenyi Biotec products and services are for research use only and not for therapeutic or diagnostic use. The CliniMACS System components, including Reagents, Tubing Sets, Instruments, and PBS/EDTA Buffer, are designed, manufactured and tested under a quality system certified to ISO 13485. In the EU, the CliniMACS System components are available as CE-marked medical devices for their respective intended use, unless otherwise stated. The CliniMACS Reagents and Biotin Conjugates are intended for *in vitro* use only and are not designated for therapeutic use or direct infusion into patients. The CliniMACS Reagents in combination with the CliniMACS System are intended to separate human cells. Miltenyi Biotec as the manufacturer of the CliniMACS System does not give any recommendations regarding the use of separated cells for therapeutic purposes and does not make any claims regarding a clinical benefit. For the manufacturing and use of target cells in humans, the national legislation and regulations – e.g. for the EU the Directive 2004/23/EC (“human tissues and cells”), or the Directive 2002/98/EC (“human blood and blood components”) – must be followed. Thus, any clinical application of the target cells is exclusively within the responsibility of the user of a CliniMACS System.

In the US, the CliniMACS CD34 Reagent System, including the CliniMACS Plus Instrument, CliniMACS CD34 Reagent, CliniMACS Tubing Sets TS and LS, and the CliniMACS PBS/EDTA Buffer, is FDA-approved as a Humanitarian Use Device (HUD), authorized by U.S. Federal law for use in the treatment of patients with acute myeloid leukemia (AML) in first complete remission. The effectiveness of the device for this indication has not been demonstrated. Other products of the CliniMACS Product Line are available for use only under an approved Investigational New Drug (IND) application, Investigational Device Exemption (IDE) or FDA approval. MACS GMP Products are for *ex vivo* cell processing only, and are not intended for human *in vivo* applications. For regulatory status in the USA, please contact your local representative. MACS GMP Products are designed, manufactured and tested under an ISO 13485 quality management system and are in compliance with relevant GMP guidelines. They are designed following the recommendations of USP <1043> on ancillary materials. The manufacturing and testing of MACS GMP Products of biological origin are in compliance with EP chapter 5.2.12 for “Raw materials of biological origin for the production of cell-based and gene therapy medicinal products”. Vectofusin is a registered trademark of Genethon.

CliniMACS, CliniMACS Prodigy, MACS, MACSQuant, StainExpress, TexMACS, TransAct, and the Miltenyi Biotec logo are registered trademarks or trademarks of Miltenyi Biotec and/or its affiliates in various countries worldwide. Copyright © 2024 Miltenyi Biotec and/or its affiliates. All rights reserved.